BookBruce E. Torbett, David S. Goodsell, Douglas D. Richman, editors.
Summary: This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle.
Contents:
HIV Therapy: Looking Towards the Future
Computational challenges of structure-based approaches applied to HIV
Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1
HIV-1 integrase multimerization as a therapeutic target
Targeting HIV transcription: The quest for a functional cure
Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder
HIV-1 Gag: An Emerging Target for Antiretroviral Therapy
The Triple Threat of HIV-1 Protease Inhibitors
Illustrations of the HIV Life Cycle.
Location
Version
Call Number
Items